Resveratrol: Biologic and therapeutic implications

Sarfaraz Sadruddin, Rohit Arora

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Resveratrol (3,4′,5 trihydroxystilbene), a naturally-occurring molecule known as a phytoalexin, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious substances; it is also known to possess an array of cardioprotective effects. Recently, studies have shown resveratrol to protect against the metabolic changes associated with hypercaloric diets in mice with induced insulin resistance, hyperglycemia, and dyslipidemia. Despite impressive gains in diagnosis and treatment, cardiovascular disease (CVD) remains a serious clinical problem and threat to public health. The metabolic syndrome, which identifies persons at higher risk for diabetes mellitus and CVD, is approaching a prevalence of nearly 25% of the western world. If the metabolic syndrome can be considered a polar opposite to caloric restriction, then agents that mimic caloric restriction may offer a new therapeutic approach to preventing CVD. The authors discuss the cardioprotective effects of resveratrol and highlight its role in glucose homeostasis and lipid metabolism in mice. Armed with the ability to prevent the deleterious effects of excess caloric intake and prevent detrimental cardiovascular events, resveratrol merits proper clinical investigations for its efficacy in treating metabolic diseases and CVD.

Original languageEnglish (US)
Pages (from-to)102-106
Number of pages5
JournalJournal of the CardioMetabolic Syndrome
Volume4
Issue number2
DOIs
StatePublished - May 4 2009
Externally publishedYes

Fingerprint

Cardiovascular Diseases
Caloric Restriction
Western World
Metabolic Diseases
Therapeutics
Dyslipidemias
Energy Intake
Lipid Metabolism
Hyperglycemia
Insulin Resistance
Diabetes Mellitus
Homeostasis
Fungi
Public Health
Diet
Bacteria
Glucose
resveratrol

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Resveratrol : Biologic and therapeutic implications. / Sadruddin, Sarfaraz; Arora, Rohit.

In: Journal of the CardioMetabolic Syndrome, Vol. 4, No. 2, 04.05.2009, p. 102-106.

Research output: Contribution to journalReview article

@article{f275dbbfee674906a6881e84707150a3,
title = "Resveratrol: Biologic and therapeutic implications",
abstract = "Resveratrol (3,4′,5 trihydroxystilbene), a naturally-occurring molecule known as a phytoalexin, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious substances; it is also known to possess an array of cardioprotective effects. Recently, studies have shown resveratrol to protect against the metabolic changes associated with hypercaloric diets in mice with induced insulin resistance, hyperglycemia, and dyslipidemia. Despite impressive gains in diagnosis and treatment, cardiovascular disease (CVD) remains a serious clinical problem and threat to public health. The metabolic syndrome, which identifies persons at higher risk for diabetes mellitus and CVD, is approaching a prevalence of nearly 25{\%} of the western world. If the metabolic syndrome can be considered a polar opposite to caloric restriction, then agents that mimic caloric restriction may offer a new therapeutic approach to preventing CVD. The authors discuss the cardioprotective effects of resveratrol and highlight its role in glucose homeostasis and lipid metabolism in mice. Armed with the ability to prevent the deleterious effects of excess caloric intake and prevent detrimental cardiovascular events, resveratrol merits proper clinical investigations for its efficacy in treating metabolic diseases and CVD.",
author = "Sarfaraz Sadruddin and Rohit Arora",
year = "2009",
month = "5",
day = "4",
doi = "10.1111/j.1559-4572.2008.00039.x",
language = "English (US)",
volume = "4",
pages = "102--106",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Resveratrol

T2 - Biologic and therapeutic implications

AU - Sadruddin, Sarfaraz

AU - Arora, Rohit

PY - 2009/5/4

Y1 - 2009/5/4

N2 - Resveratrol (3,4′,5 trihydroxystilbene), a naturally-occurring molecule known as a phytoalexin, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious substances; it is also known to possess an array of cardioprotective effects. Recently, studies have shown resveratrol to protect against the metabolic changes associated with hypercaloric diets in mice with induced insulin resistance, hyperglycemia, and dyslipidemia. Despite impressive gains in diagnosis and treatment, cardiovascular disease (CVD) remains a serious clinical problem and threat to public health. The metabolic syndrome, which identifies persons at higher risk for diabetes mellitus and CVD, is approaching a prevalence of nearly 25% of the western world. If the metabolic syndrome can be considered a polar opposite to caloric restriction, then agents that mimic caloric restriction may offer a new therapeutic approach to preventing CVD. The authors discuss the cardioprotective effects of resveratrol and highlight its role in glucose homeostasis and lipid metabolism in mice. Armed with the ability to prevent the deleterious effects of excess caloric intake and prevent detrimental cardiovascular events, resveratrol merits proper clinical investigations for its efficacy in treating metabolic diseases and CVD.

AB - Resveratrol (3,4′,5 trihydroxystilbene), a naturally-occurring molecule known as a phytoalexin, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious substances; it is also known to possess an array of cardioprotective effects. Recently, studies have shown resveratrol to protect against the metabolic changes associated with hypercaloric diets in mice with induced insulin resistance, hyperglycemia, and dyslipidemia. Despite impressive gains in diagnosis and treatment, cardiovascular disease (CVD) remains a serious clinical problem and threat to public health. The metabolic syndrome, which identifies persons at higher risk for diabetes mellitus and CVD, is approaching a prevalence of nearly 25% of the western world. If the metabolic syndrome can be considered a polar opposite to caloric restriction, then agents that mimic caloric restriction may offer a new therapeutic approach to preventing CVD. The authors discuss the cardioprotective effects of resveratrol and highlight its role in glucose homeostasis and lipid metabolism in mice. Armed with the ability to prevent the deleterious effects of excess caloric intake and prevent detrimental cardiovascular events, resveratrol merits proper clinical investigations for its efficacy in treating metabolic diseases and CVD.

UR - http://www.scopus.com/inward/record.url?scp=65349091486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349091486&partnerID=8YFLogxK

U2 - 10.1111/j.1559-4572.2008.00039.x

DO - 10.1111/j.1559-4572.2008.00039.x

M3 - Review article

C2 - 19614797

AN - SCOPUS:65349091486

VL - 4

SP - 102

EP - 106

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 2

ER -